Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195013 · ClinicalTrials.gov registry record · Phase 3
Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00195013 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 30 participants.
The verdict
NCT00195013, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.
Interventions
- DRUG Placebo
- DRUG glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195013
The ClinicalTrials.gov registry entry for NCT00195013 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00195013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195013 about?
NCT00195013 is a clinical study titled "Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy". Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.
What is the current status of trial NCT00195013?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2003-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00195013?
The interventions under investigation include: Placebo (DRUG), glutamine (DRUG).
Who is sponsoring clinical trial NCT00195013?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.